Orexigen Therapeutics Inc., of San Diego, reported a first quarter loss of 14 cents per share on net sales of $11.5 million, all attributable to the first full quarter of the company's obesity drug Contrave (naltrexone and bupropion) following its October 2014 U.S. launch.